Shares of AbCellera Biologics (NASDAQ: ABCL) surged 6.13% in after-hours trading on Thursday following the release of its second-quarter earnings report, which significantly exceeded analyst expectations.

The biotechnology company reported a quarterly loss of $0.12 per share, outperforming the analyst consensus estimate of a $0.15 loss by 21.05%. This result also showed improvement compared to the $0.13 loss per share reported in the same quarter last year. More impressively, AbCellera's quarterly sales skyrocketed to $17.084 million, crushing the analyst consensus estimate of $5.824 million by a whopping 193.31%. This figure represents a substantial 133.29% increase from the $7.323 million in sales recorded in the same period last year.

The strong financial performance, particularly the remarkable sales growth, appears to have boosted investor confidence in AbCellera Biologics. The company's ability to significantly beat both earnings and revenue estimates suggests potential for continued growth and improved financial health, factors that likely contributed to the stock's after-hours rally. As the market digests this positive earnings surprise, investors will be watching closely to see if the upward momentum continues in the coming trading sessions.